Astrabio, a global innovator in neurobiomarker detection, was honored to participate as a special guest at the signing ceremony of the Memorandum of Understanding between Eisai (Thailand) Marketing Co., Ltd.and Bangkok Genomics Innovation PLC.

Suzhou AstraBio Technology Co. Ltd has helped to complete a study on the diagnostic performance of four plasma biomarkers (GFAP, α-syn, NfL, p-tau181) in FTD patients based on a single-molecule immunoassay technology.

Suzhou AstraBio Technology Co. Ltd has successfully obtained NMPA for two single-molecule-based blood test kits: GFAP Protein Assay and NFL Protein Assay.

Suzhou AstraBio Technology Co. Ltd completed tens of millions of yuan Pre-B+ round of financing, the future of immunoassay technology high-end brand as the goal, to accelerate the AD early screening and early diagnosis market layout.

Suzhou AstraBio Technology Co. Ltd has completed tens of millions of yuan of Pre-B round of financing, will be the core of the neurological markers, to further improve the neurological blood markers screening and diagnostic solutions.

AD blood reagents kit based on single-molecule analysis strategy successfully receives NMPA approved: β Amyloid 1-42 reagents kit Phosphorylated tau 181 reagents kit

ASTRABIO passed the ISO 13485:2016 medical device quality management system certification.

The fully automated single-molecule immunoassay analyzer AST-DxSMD developed by ASTRABIO has now under registration for application as an innovative medical device.

ASTRABIO completed nearly 100 million CNY Series A financing to create a closed-loop industrial chain for clinical transformation of novel biomarkers.

Our first fully automated fluorescence immunoassay analyzer based on single-molecule analysis strategy approved as Class II medical device.

ASTRABIO acquired Xiamen Memorigen Biomedical Technology Co., Ltd.

ASTRABIO was established in Suzhou